Multi-Biomarker RA Activity Scoring With Adjusted Clinical Variables
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical assessments for rheumatoid arthritis (RA) are subjective, invasive, time-consuming, and lack specificity, while biomarker-based tests face challenges due to the complexity of RA biology and interference from rheumatoid factor, limiting their effectiveness in predicting disease activity and progression.
Innovation Solution
A method using a multiplex assay to generate a disease activity score by combining the expression of multiple protein biomarkers (CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, SAA1, TNFRSF1A, VCAM1, VEGFA) with predefined coefficients, and incorporating clinical variables like age, gender, and BMI, to provide a quantitative and objective assessment of RA activity and predict radiographic progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical assessments (DAS, CDAI, SDAI) are used to evaluate RA disease activity, then clinical variables such as joint swelling, tenderness, and morning stiffness can be measured, but the assessments are subjective, invasive, time-consuming, and lack specificity
Solution Approach 1:
The patent replaces manual clinical assessment methods (physical examination of joints, patient questionnaires) with a laboratory-based biomarker assay system. The multiplex assay automatically detects and quantifies protein biomarkers in blood samples, eliminating the need for invasive physical manipulation of joints and subjective clinical scoring, thereby reducing invasiveness and time consumption while improving measurement precision and specificity
Solution Approach 2:
The patent introduces blood-based protein biomarkers as intermediary molecules that mediate the detection of disease activity. Instead of directly measuring joint inflammation through physical examination, the assay detects circulating biomarkers (such as chitinase 3-like 1, C-reactive protein, epidermal growth factor, interleukin 6, leptin, matrix metallopeptidase 1, matrix metallopeptidase 3, resistin, serum amyloid A1, tumor necrosis factor receptor superfamily member 1A, vascular cell adhesion molecule 1, and vascular endothelial growth factor A) that reflect underlying inflammatory processes, providing an indirect but more precise and non-invasive measure of disease activity
2Measurement precision
If biomarker-based tests are used to assess RA activity, then objective measurement can be achieved, but the tests face challenges due to the complexity of RA biology and interference from rheumatoid factor
Solution Approach 1:
The patent segments the complex RA biology into distinct measurable components by selecting specific protein biomarkers that are individually detectable and quantifiable. The multiplex assay measures multiple biomarkers simultaneously, each contributing specific information about different aspects of disease activity, thereby simplifying the overall complexity of RA pathogenesis into measurable parameters while maintaining objectivity
Solution Approach 2:
The patent addresses rheumatoid factor interference by changing the measurement parameters and assay conditions. The multiplex assay uses specific detection reagents and quantification methods that are calibrated to distinguish target biomarkers from interfering substances like rheumatoid factor. By adjusting assay parameters and using validated biomarker panels, the system maintains objective measurement capability despite the presence of interfering factors
3Measurement precision
If multiple biomarkers are combined with predefined coefficients to generate a disease activity score, then a quantitative assessment can be provided, but the method becomes more complex
Solution Approach 1:
The patent merges multiple biomarker measurements into a single integrated disease activity score by combining the quantitative values of individual biomarkers (CHI3L1, CRP, EGF, IL6, LEP, MMP1, MMP3, SAA1, TNFRSF1A, VCAM1, VEGFA) using predefined coefficients. This consolidation transforms complex multi-parameter data into one unified quantitative metric that maintains high measurement precision while simplifying the output for clinical interpretation and decision-making
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method offers a more accurate and consistent evaluation of RA disease activity, enabling personalized therapy recommendations by predicting radiographic progression and joint damage, reducing subjectivity and invasiveness in clinical assessments.
Implementation Method 1
The method comprises performing an immunoassay on a blood sample from the subject to generate a test expression score comprising protein level data for at least two protein markers
Data Source
AI summary
Provided herein are methods for assessing response to inflammatory disease therapy. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers to assess disease activity in inflammatory diseases, e.g., rheumatoid arthritis. Also provided are methods of adjusting disease activity scores to account for variables that can influence such scores.